PRISMA harms checklist: improving harms reporting in systematic reviews - PubMed (original) (raw)
PRISMA harms checklist: improving harms reporting in systematic reviews
Liliane Zorzela et al. BMJ. 2016.
Erratum in
- PRISMA harms checklist: improving harms reporting in systematic reviews.
[No authors listed] [No authors listed] BMJ. 2016 Apr 19;353:i2229. doi: 10.1136/bmj.i2229. BMJ. 2016. PMID: 27094210 No abstract available.
Abstract
Introduction: For any health intervention, accurate knowledge of both benefits and harms is needed. Systematic reviews often compound poor reporting of harms in primary studies by failing to report harms or doing so inadequately. While the PRISMA statement (Preferred Reporting Items for Systematic reviews and Meta-Analyses) helps systematic review authors ensure complete and transparent reporting, it is focused mainly on efficacy. Thus, a PRISMA harms checklist has been developed to improve harms reporting in systematic reviews, promoting a more balanced assessment of benefits and harms.
Methods: A development strategy, endorsed by the EQUATOR Network and existing reporting guidelines (including the PRISMA statement, PRISMA for abstracts, and PRISMA for protocols), was used. After the development of a draft checklist of items, a modified Delphi process was initiated. The Delphi consisted of three rounds of electronic feedback followed by an in-person meeting.
Results: The PRISMA harms checklist contains four essential reporting elements to be added to the original PRISMA statement to improve harms reporting in reviews. These are reported in the title ("Specifically mention 'harms' or other related terms, or the harm of interest in the review"), synthesis of results ("Specify how zero events were handled, if relevant"), study characteristics ("Define each harm addressed, how it was ascertained (eg, patient report, active search), and over what time period"), and synthesis of results ("Describe any assessment of possible causality"). Additional guidance regarding existing PRISMA items was developed to demonstrate relevance when synthesising information about harms.
Conclusion: The PRISMA harms checklist identifies a minimal set of items to be reported when reviewing adverse events. This guideline extension is intended to improve harms reporting in systematic reviews, whether harms are a primary or secondary outcome.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Similar articles
- The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. Hutton B, et al. Ann Intern Med. 2015 Jun 2;162(11):777-84. doi: 10.7326/M14-2385. Ann Intern Med. 2015. PMID: 26030634 - Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement.
McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group; Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. McInnes MDF, et al. JAMA. 2018 Jan 23;319(4):388-396. doi: 10.1001/jama.2017.19163. JAMA. 2018. PMID: 29362800 - Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Aiyegbusi OL, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Elsman EBM, et al. Health Qual Life Outcomes. 2024 Jul 9;22(1):48. doi: 10.1186/s12955-024-02256-9. Health Qual Life Outcomes. 2024. PMID: 38978063 Free PMC article. - Quality of reporting in systematic reviews of adverse events: systematic review.
Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, Loke Y, Vohra S. Zorzela L, et al. BMJ. 2014 Jan 8;348:f7668. doi: 10.1136/bmj.f7668. BMJ. 2014. PMID: 24401468 Free PMC article. Review. - Systematic reviews in orthodontics: Impact of the PRISMA for Abstracts checklist on completeness of reporting.
Vásquez-Cárdenas J, Zapata-Noreña Ó, Carvajal-Flórez Á, Barbosa-Liz DM, Giannakopoulos NN, Faggion CM Jr. Vásquez-Cárdenas J, et al. Am J Orthod Dentofacial Orthop. 2019 Oct;156(4):442-452.e12. doi: 10.1016/j.ajodo.2019.05.009. Am J Orthod Dentofacial Orthop. 2019. PMID: 31582116 Review.
Cited by
- Risk of cancer development associated with disease-modifying therapies for multiple sclerosis: study protocol for a systematic review and meta-analysis of randomised and non-randomised studies.
Catalá-López F, Tejedor-Romero L, Driver JA, Hutton B, Sánchez-Ortí JV, Ridao M, Alonso-Arroyo A, Correa-Ghisays P, Forés-Martos J, Balanzá-Martínez V, Valencia A, Cobos I, Tabarés-Seisdedos R. Catalá-López F, et al. Syst Rev. 2024 Oct 18;13(1):263. doi: 10.1186/s13643-024-02677-z. Syst Rev. 2024. PMID: 39425150 Free PMC article. - Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.
Morice PM, Khalife-Hachem S, Sassier M, Lelong-Boulouard V, Danu A, Pasquier F, Renneville A, Dolladille C, Micol JB. Morice PM, et al. Blood Cancer J. 2024 Oct 14;14(1):177. doi: 10.1038/s41408-024-01154-z. Blood Cancer J. 2024. PMID: 39402057 Free PMC article. No abstract available. - The impact of patient engagement on patient safety in care transitions after cancer treatment: Protocol for a systematic review and meta-analysis.
Brust L, Schmidt-Wolf I, Weigl M. Brust L, et al. PLoS One. 2024 Aug 27;19(8):e0307831. doi: 10.1371/journal.pone.0307831. eCollection 2024. PLoS One. 2024. PMID: 39190692 Free PMC article. - Accelerating evidence synthesis for safety assessment through ClinicalTrials.gov platform: a feasibility study.
Yu T, Yang X, Clark J, Lin L, Furuya-Kanamori L, Xu C. Yu T, et al. BMC Med Res Methodol. 2024 Jul 30;24(1):165. doi: 10.1186/s12874-024-02225-2. BMC Med Res Methodol. 2024. PMID: 39080524 Free PMC article. - Protocol for the development of a reporting guideline for umbrella reviews on epidemiological associations using cross-sectional, case-control and cohort studies: the Preferred Reporting Items for Umbrella Reviews of Cross-sectional, Case-control and Cohort studies (PRIUR-CCC).
Solmi M, Cobey K, Moher D, Ebrahimzadeh S, Dragioti E, Shin JI, Radua J, Cortese S, Shea B, Veronese N, Hartling L, Pollock M, Egger M, Papatheodorou S, Ioannidis JP, Carvalho AF. Solmi M, et al. BMJ Open. 2024 Jun 17;14(6):e071136. doi: 10.1136/bmjopen-2022-071136. BMJ Open. 2024. PMID: 38889936 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources